Tildrakizumab in the treatment of psoriasis – literature review

• Main Author: Katarzyna Banaszczyk
• Format: Article
• Language: English
• Published: Termedia Publishing House 2019-08-01
• Series: Rheumatology
• Subjects: psoriasis; antibodies; interleukins; tildrakizumab
• Online Access: https://www.termedia.pl/Tildrakizumab-in-the-treatment-of-psoriasis-literature-review,18,37542,1,1.html

Psoriasis is a chronic, inflammatory disease. The incidence of its occurrence in developed countries is 1–4%. The aim of this study is to present the current state of knowledge and characterize the antibody tildrakizumab, which in March 2018 was approved by the FDA agency for use in adult patients with moderate to severe plaque psoriasis. The work presents the mechanism of action of tildrakizumab and the way it affects the immunological pathways associated with the pathogenesis of psoriasis. Recent studies indicate that interleukin 23 and its p19 subunit are a key target in the effective treatment of psoriasis. The paper also presents the latest clinical trials that present the safety profile and efficacy of tildrakizumab in the treatment of psoriasis. According to clinical trials, tildrakizumab is an effective and safe drug for use in adult patients in the treatment of moderate to severe psoriasis.